Literature DB >> 10343098

Physical mapping of the CXC chemokine locus on human chromosome 4.

N O'Donovan1, M Galvin, J G Morgan.   

Abstract

A physical map of the CXC chemokine locus on chromosome 4 has been constructed by PCR analysis and PFGE mapping of YAC clones. The genes for IL8, GRO1, PPBP, PF4, SCYB5 (ENA-78) and SCYB6 (GCP-2) have been co-localized on a 335-kb genomic fragment. The GRO2 and GRO3 genes did not map within this region and based on analysis of a YAC contig overlapping IL8 we speculate that GRO2 and GRO3 map downstream of this region. We have also assigned the novel CXC chemokine gene, SCYB9B (alias H174/betaR1) to chromosome 4q21, upstream and within 12 kb of INP10. Like INP10 and MIG, INP10 and SCYB9B are arranged in a head to tail manner. The chromosomal arrangement of these genes appears to reflect the evolution of this multigene family and supports the theory that it arose by gene duplication.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10343098     DOI: 10.1159/000015209

Source DB:  PubMed          Journal:  Cytogenet Cell Genet        ISSN: 0301-0171


  17 in total

1.  Inflammatory cytokine and chemokine expression in sympathetic ophthalmia: a pilot study.

Authors:  Emiko Furusato; DeFen Shen; Xiaoguang Cao; Bungo Furusato; Robert B Nussenblatt; Elisabeth J Rushing; Chi-Chao Chan
Journal:  Histol Histopathol       Date:  2011-09       Impact factor: 2.303

Review 2.  Chemokine signaling in cancer-stroma communications.

Authors:  Arun J Singh; Joe W Gray
Journal:  J Cell Commun Signal       Date:  2021-06-04       Impact factor: 5.782

3.  Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis.

Authors:  Xiaohui Zhang; Pengfei Li; Junying Bao; Santo V Nicosia; Honggang Wang; Steven A Enkemann; Wenlong Bai
Journal:  J Biol Chem       Date:  2005-08-10       Impact factor: 5.157

4.  Modulation of cystic fibrosis lung disease by variants in interleukin-8.

Authors:  A D Hillian; D Londono; J M Dunn; K A B Goddard; R G Pace; M R Knowles; M L Drumm
Journal:  Genes Immun       Date:  2008-06-19       Impact factor: 2.676

5.  NMR structure of CXCR3 binding chemokine CXCL11 (ITAC).

Authors:  Valerie Booth; Ian Clark-Lewis; Brian D Sykes
Journal:  Protein Sci       Date:  2004-08       Impact factor: 6.725

6.  Role of immunoreactions and mast cells in pathogenesis of human endometriosis--morphologic study and gene expression analysis.

Authors:  Ryo Konno; Hisafumi Yamada-Okabe; Hiroyuki Fujiwara; Ichiro Uchiide; Hiroaki Shibahara; Michitaka Ohwada; Tomomi Ihara; Masao Sugamata; Mitsuaki Suzuki
Journal:  Hum Cell       Date:  2003-09       Impact factor: 4.174

7.  Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2.

Authors:  Alessandro Antonelli; Poupak Fallahi; Silvia Martina Ferrari; Alda Corrado; Marco Sebastiani; Dilia Giuggioli; Mario Miccoli; Anna Linda Zignego; Domenico Sansonno; Santino Marchi; Clodoveo Ferri
Journal:  Clin Rheumatol       Date:  2013-04-05       Impact factor: 2.980

8.  p38 Mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts.

Authors:  Mathias A E Frevel; Tala Bakheet; Aristobolo M Silva; John G Hissong; Khalid S A Khabar; Bryan R G Williams
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

9.  Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation.

Authors:  Cheng-Jun Hu; Li-Yi Wang; Lewis A Chodosh; Brian Keith; M Celeste Simon
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

10.  Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.

Authors:  Pascale Lévy; Dominique Vidaud; Karen Leroy; Ingrid Laurendeau; Janine Wechsler; Giulia Bolasco; Béatrice Parfait; Pierre Wolkenstein; Michel Vidaud; Ivan Bièche
Journal:  Mol Cancer       Date:  2004-07-15       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.